Monoclonal antibodies produced by Regeneron and Eli Lilly have become widely accepted as a successful treatment for COVID-19, reducing symptoms quickly and keeping infected people out of the hospital if they act quickly enough. Doctors and vaccine skeptics alike are proponents, but some medical experts argue the antibodies aren't enough on their own to make up for the slow-down in vaccine uptake, The New York Times reports.
The simple explanation is that the more people who get vaccinated, the fewer people there will be who need any sort of coronavirus remedy. Beyond that, the infusions also take a lot of time and require a lot of attention from hospital staff. They're also more expensive, costing the federal government about $2,100 per dose. "It's clogging up resources, it's hard to give, and a vaccine is $20 and could prevent almost all of that," Dr. Christian Ramers, an infectious disease specialist and the chief of population health at Family Health Centers of San Diego, told the Times. Basically, Ramers said, emphasizing monoclonal antibodies and playing down vaccines is akin to "investing in car insurance without investing in brakes."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Passenger jet, Blackhawk helicopter collide in DCSpeed Read An American Airlines flight with 64 people aboard collided with an Army helicopter, and no survivors have been found
-
White House withdraws Trump's spending freezeSpeed Read President Donald Trump's budget office has rescinded a directive that froze trillions of dollars in federal aid and sowed bipartisan chaos
-
Washington DC plane crash: how did mid-air collision happen?Today's Big Question Experts struggle to explain how sophisticated airspace control system failed to prevent deadly disaster
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
How close are we to a norovirus vaccine?Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
-
Marty Makary: the medical contrarian who will lead the FDAIn the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
-
ACA opens 2025 enrollment, enters 2024 raceSpeed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
-
McDonald's sued over E. coli linked to burgerSpeed Read The outbreak has sickened at least 49 people in 10 states and left one dead
